H.C. Wainwright raised the firm’s price target on Ultragenyx (RARE) to $95 from $82 and keeps a Buy rating on the shares post the Q3 report. The firm believes the company’s path to profitability in 2026 is achievable.
H.C. Wainwright raised the firm’s price target on Ultragenyx (RARE) to $95 from $82 and keeps a Buy rating on the shares post the Q3 report. The firm believes the company’s path to profitability in 2026 is achievable.